SEARCH

SEARCH BY CITATION

References

  • 1
    Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357:536.
  • 2
    Askie LM, Duley L, Henderson-Smart D, Stewart LA, on behalf of the PARIS Collaboration Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:17918.
  • 3
    Hofmeyr GJ, Duley L, Atallah A. Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary. BJOG 2007;114:93343.
  • 4
    Raty R, Koskinen P, Alanen A, Irjala K, Matilauri I, Ekblad U, et al. Prediction of pre-eclampsia with maternal mid-trimester total renin, inhibin A, AFP and free beta-hCG levels. Prenat Diagn 1999;19:1227.
  • 5
    Yaron Y, Cherry M, Kramer RL. Second trimester maternal serum screening: maternal serum α-fetoprotein, β-chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999;181:96874.
  • 6
    Gonen R, Perez R, David M, Dar H, Merkshamer R, Sharf M. The association between unexplained second trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 1992;80:836.
  • 7
    Aqualina J, Maplethorpe R, Ellis P, Harrington K. Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotrophin for the prediction of pre-eclampsia. Placenta 2000;21:48792.
  • 8
    Ashour AMN, Liberman ES, Wilkins Haug LE, Repke JT. The value of elevated second trimester beta-human chorionic gonadotropin in predicting development of preeclampsia. Am J Obstet Gynecol 1997;176:43842.
  • 9
    Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin-A and inhibin-A as possible endocrine markers for preeclampsia. Lancet 1997;349:12858.
  • 10
    Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, et al. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 2000;15:16405.Erratum in Hum Reprod 2001;16:2477.
  • 11
    Spencer K, Yu CKH, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first trimester maternal serum PAPP-A and free β-hCG and with second trimester uterine artery Doppler. Prenat Diagn 2005;25:94953.
  • 12
    Sorensen TK, Malinow MR, Williams MA, King IB, Luthy DA. Elevated second trimester serum homocysteine levels and subsequent risk of pre-eclampsia. Gynecol Obstet Invest 1999;48:98103.
  • 13
    Wolf M, Sandler L, Muñoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002;87:15638.
  • 14
    Thadhani H, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004;89:7705.
  • 15
    Levine RJ, Manyard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk for preeclampsia. N Engl J Med 2004;350:67283.
  • 16
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating anti-angiogenic factors in preeclampsia. N Engl J Med 2006;355:9921005.
  • 17
    Florio P, Imperatore A, Sanseverino F, Torricelli M, Reis FM, Lowry PJ, et al. The measurement of maternal plasma corticotropin-releasing factor (CRF) and CRF-binding protein improves the early prediction of preeclampsia. J Clin Endocrinol Metab 2004;89:46737.
  • 18
    Papageorghiou AT, Yu CKH, Cicero S, Bower S, Nicolaides KH. Second-trimester uterine artery Doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med 2002;12:7888.
  • 19
    Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2002;18:5836.
  • 20
    Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, et al. Placental protein 13 (PP13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004;25:60822.
  • 21
    Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem 2004;271:106578.
  • 22
    Visegrady B, Than NG, Kiler F, Sumegi B, Than GN, Bohn H. Homology modeling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). Protein Eng 2001;14:87580.
  • 23
    Samar M, Sadan O, Fleischafab Z, Meiri H, Huppertz B, Golan A. Molecular and cellular impacts of placenta-related pathologies on PP13 in complicated premature deliveries. Am J Obstet Gynecol 2005;193 (Suppl):S77.
  • 24
    Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first trimester screening for early pre-eclampsia combining serum PP13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2005;27:1317.
  • 25
    Spencer K, Cowans NJ, Chafetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007;29:12834.
  • 26
    Chefetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007;197:35.e135.e7.
  • 27
    Brown MA, Lindheimer MD, De Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IXXIV.
  • 28
    Cuckle HS, Wald N. Testing using single markers. In: WaldN, LeckI, editors. Antenatal and Neonatal Screening, 2nd edn. Oxford, UK: Oxford University Press; 2000. pp.122.
  • 29
    Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, Meiri H. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn 2007;27:25863.
  • 30
    Vainio M, Kujansuu E, Iso-Mustajärvi M, Mäenpää J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002;109:1617.
  • 31
    Chiaffarino F, Parazzini F, Paladini D, Acaia B, Ossola W, Marozio L, et al. A small randomised trial of low-dose aspirin in women at high risk of pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2004;112:1424.
  • 32
    Than NG, Sumegi B, Than GN, Berente Z, Bohn H. Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden crystal protein. Placenta 1999;20:70310.
  • 33
    Huppertz B, Kingdom JC. Apoptosis in the trophoblast – role of apoptosis in placental morphogenesis. J Soc Gynecol Investig 2004;11:35362.
  • 34
    Huppertz B. Placental villous trophoblast: the altered balance between proliferation and apoptosis triggers pre-eclampsia. J Rep Med Endocrinol 2006;3:1038.